share_log

Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma

Benzinga ·  Apr 24, 2023 07:34
Soligenix Submits Type A Meeting Request To US FDA To Review Proposed Study Design For A Second Phase 3 Study Evaluating HyBryte In The Treatment Of Cutaneous T-Cell Lymphoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment